Cardioversion can improve heart function, reduce the risk of embolism and relieve symptoms in patients with atrial fibrillation. Despite anticoagulation therapy, thromboembolic complications can still ...

May 2, 2003 - A retrospective study and results of a phase 3 trial point to new approaches to both short-term cardioversion and long-term maintenance of patients with atrial fibrillation (AF).

Nicholas P. Gall, M.Sc., M.D., M.R.C.P.; Francis D. Murgatroyd, M.A., F.R.C.P., F.A.C.C. From these and subsequent studies, it became clear that cardioversion was ...

Atrial fibrillation (AFib) is a kind of irregular heartbeat, or arrhythmia. A problem with the electrical signals that control your heart’s pumping action causes it to beat too fast in a pattern that ...

Endurance athletes may be at increased risk for lone atrial fibrillation. 1–5 We describe a middle-aged physician athlete with paroxysmal lone atrial fibrillation in whom cardioversion consistently ...

Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: ...

Global LEADR clinical trial meets safety and effectiveness objectives; results presented at Heart Rhythm 2024 and simultaneously published in Heart Rhythm Implantable cardioverter defibrillators (ICDs ...

(MENAFN- PR Newswire) Separately, the company is also studying placing the novel, small-diameter OmniaSecure defibrillation lead in the left bundle branch (LBB) area, which has the potential to enable ...

Medtronic plc, a global leader in healthcare technology, received US Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The ...

Medtronic has warned that one of the models in its Vanta range of implantable neurostimulators for pain relief may stop working if the patient is given cardioversion therapy to restore a normal heart ...